STOCK TITAN

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

Investors can access Lexeo’s Stifel 2026 Virtual Cardiometabolic Forum fireside chat via live webcast and on-demand replay on the company website.

(Moderate)
(Neutral)
Tags

Lexeo Therapeutics (LXEO) will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026, at 9:00 a.m. ET.

The discussion will be webcast live under the Events & Presentations tab in the Investors section of the company’s website. A replay of the webcast will be available on the Lexeo website following the presentation, allowing those who cannot attend live to view the session later.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET.

The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Media Response:
Media@lexeotx.com

Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can investors watch Lexeo Therapeutics’ presentation at the Stifel 2026 Virtual Cardiometabolic Forum?

The fireside chat will be webcast live under the Events & Presentations tab in the Investors section of Lexeo Therapeutics’ website. A replay of the webcast will also be available on the company’s website after the presentation.

When is Lexeo Therapeutics scheduled to present at the Stifel 2026 Virtual Cardiometabolic Forum?

Lexeo Therapeutics is scheduled to participate in a fireside chat on September 30, 2026, at 9:00 a.m. Eastern Time.

Keep reading